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Abstract
Objective: The synergistic effects of VL and long wavelength UVA1 (VL + UVA1,
370–700 nm) on inducing pigmentation and erythema in skin have been demonstrated and linked to exacerbation of dermatologic conditions including melasma
and post-inflammatory hyperpigmentation. This study aimed to compare the
photoprotection of organic sunscreens enriched with antioxidant (AO) combinations against VL + UVA1 induced biologic effects. The efficacy was compared
with that offered by a commercially available tinted sunscreen.
Methods: Ten healthy adult subjects with Fitzpatrick skin phototypes IV–
VI were enrolled (nine completed). VL + UVA1 dose of 380 J/cm2 was utilized.
Assessment methods were polarized photography, investigator global scoring and
diffuse reflectance spectroscopy (DRS). Measurements were obtained at baseline
and immediately, 24 h and 7 days after irradiation.
Results: Sites treated with tinted sunscreen product had significantly less pigmentation compared with untreated but irradiated skin at all time points.
However, DRS results demonstrated that the 5-AO sunscreen performed comparably or better than all sunscreens tested with relatively lower dyschromia, delayed erythema and pigmentation.
Conclusion: These results highlight the potential of AO-enriched sunscreens to
be photoprotective against VL + UVA1. The combination of efficacy and the cosmetic appearance of this product may provide wider acceptability which is crucial
considering the limited available means of protection against this waveband.
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ANTIOXIDANT SUNSCREENS FOR UVA1 AND VISIBLE LIGHT

  

Résumé
Objectif: les effets synergiques de la lumière visible (LV) et des rayons ultraviolets long (UVA1) (LV + UVA1, 370 à 700 nm) sur l’induction de la pigmentation
et de l’érythème cutané ont été démontrés et liés à l’exacerbation des affections
dermatologiques, notamment le mélasma et l’hyperpigmentation post-inflammatoire. Cette étude visait à comparer la photoprotection des écrans solaires organiques enrichis en associations antioxydantes (AO) contre les effets biologiques
induits par LV+UVA1. L’efficacité a été comparée à celle offerte par un écran
solaire teinté disponible dans le commerce.
Méthodes: dix sujets adultes en bonne santé présentant des phototypes cutanés
de Fitzpatrick IV à VI ont été inclus (neuf ont terminé l’étude). On a utilisé une
dose LV+UVA1 de 380 J/cm2. Les méthodes d’évaluation étaient la photographie
polarisée, le score global de l’investigateur et la spectroscopie de réflectance diffuse (DRS). Les mesures ont été obtenues immédiatement à l’entrée dans l’étude
et, 24 h et 7 jours après l’irradiation.
Résultats: les sites traités avec un produit de protection solaire teinté présentaient une pigmentation significativement inférieure à celle de la peau non traitée
mais irradiée, à toutes les heures de mesure. Cependant, les résultats de la DRS
ont démontré que l’écran solaire 5-AO fonctionnait de manière comparable ou
mieux que tous les écrans solaires testés avec une dyschromie, un érythème retardé et une pigmentation relativement plus faible.
Conclusion: ces résultats mettent en évidence le potentiel des écrans solaires enrichis en AO comme facteur de photoprotection contre LV+UVA1. La combinaison de l’efficacité et de l’aspect esthétique de ce produit peut permettre une plus
grande acceptabilité, ce qui est essentiel compte tenu de la disponibilité limitée
des moyens de protection contre cette gamme d’ondes.

I N T RO DU CT ION
Solar radiation from visible light (VL, 400–700 nm) incites
skin damage associated with persistent hyperpigmentation, erythema, extracellular-matrix degrading enzymes
and free-radical formation [1–9]. Additionally, synergistic effects of VL and long wavelength UVA1 (VL + UVA1,
370–700 nm) have been demonstrated on pigmentation
and erythema in melanocompetent (Fitzpatrick skin types
IV–VI), and erythema in light skin (Fitzpatrick skin types
I–III) individuals [1, 3, 6, 10]. These results have generated
interest and research on the photobiology of VL + UVA1,
and on photoprotection against their associated cutaneous
effects.
Pigmentary changes caused by VL + UVA1 have been
shown to occur in three phases: immediate pigment
darkening (IPD) which is dose dependent and lasts up
to 2 h after irradiation, followed by persistent pigment
darkening (PPD) that continues up to 24 h, and lastly delayed tanning (DT) which occurs approximately 5–7 days
after irradiation and may last from weeks to months.

Both IPD and PPD are suggested to be caused by oxidation and redistribution of pre-existing melanin, whereas
delayed tanning is exhibited by the formation of new
melanin [11, 12].
Despite VL + UVA1 being associated with pigment
darkening and worsening of conditions such as post-
inflammatory hyperpigmentation and melasma, there
are limited photoprotective options available against
this waveband. Currently available organic (chemical) filters do not offer any protection, but tinted sunscreens containing iron oxide or pigmentary titanium
dioxide do [13–17]. The fern Polypodium leucotomos extract has been shown to down-regulate VL induced pigment darkening when used as an oral supplement and
may contribute to protection against VL + UVA1 [18].
Additionally, a recent clinical study showed efficacy of
an antioxidant (AO) blend, containing diethylhexyl syringylidene malonate, vitamin C and vitamin E, in offering protection against VL + UVA1 induced erythema
in light skinned individuals and pigmentation in dark
skinned individuals [19]. With VL + UVA1 induced
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Products tested

Products

Description

Sunscreen formula actives/
concentration

AO blend/concentration

U

Untreated Irradiated Control

No sunscreen

No antioxidants

A

Sunscreen Base SPF 50 no AO

Avobenzone 3%; Octocrylene
10%; Homosalate 10%;
Octisalate 5%

No antioxidants

B

Sunscreen Base SPF 50 + 3 AO blend

Avobenzone 3%; Octocrylene
10%; Homosalate 10%;
Octisalate 5%

Diethylhexyl syringylidene malonate 1%,
Vitamin E 0.25% and Ascorbyl Palmitate
0.01%

C

Sunscreen Base SPF 50 + 5 AO blend

Avobenzone 3%; Octocrylene
10%; Homosalate 10%;
Octisalate 5%

Diethylhexyl syringylidene malonate 0.5%,
Vitamin E 0.25%, Vitamin C 0.01%,
Licochalcone A 0.025%, Glycyrrhetinic
acid 0.01%

D

Commercial Tinted Sunscreen SPF 20

TiO2 10.66% + iron oxides

Tocopheryl acetate

T A B L E 2 Description of Investigator’s Global Assessment
scores for pigmentation
IGA score

Description

0

None

2

Mild darkening of the skin

4

Moderate darkening of the skin

6

Marked darkening of the skin

8

Severe darkening of the skin

effects primarily being mediated by reactive oxygen species (ROS), these findings support the hypothesis that
AOs may have a role in mitigating VL + UVA1 effects
and should be incorporated in photoprotection [9, 19].
The efficacy of sunscreen products fully formulated with
AOs as ingredients, however, needs to be determined.
This study evaluated the efficacy of two AO-enriched
sunscreen products against VL + UVA1 induced effects.
Efficacy was compared with that offered by a commercially available tinted sunscreen product.

M AT E R I A L S AN D MET H ODS
Ten (10) subjects with SPT IV-VI were enrolled and nine
(9) completed the study (9 females; 3 with SPT IV, 3 with
SPT V and 3 with SPT VI). The study was approved by
Allendale Investigational Review Board and conducted
at Dermico Laboratory Broomall, Pennsylvania. Written
informed consent was obtained from all subjects. All
guidelines from the Declaration of Helsinki, good clinical
practice (GCP) and international conference on harmonization (ICH) were followed. Those with healthy skin, age
18 or older, with sufficient area on the back with even skin
tone and no interfering conditions/marks were included.

Subjects that had a current skin condition on their back
(e.g. psoriasis, eczema, atopic dermatitis, etc., or active
cancer) that the investigator or designee deemed inappropriate for participation or interfered with the outcome of
the study, currently taking any anti-inflammatory drugs
(e.g. aspirin, ibuprofen, Celebrex [COX-2 inhibitor], corticosteroids), immunosuppressive drugs, or antihistamine
medications or had a history of a confirmed or suspected
COVID-
19 infection within 30 days prior to the study
visit or had contact with a COVID-19-infected individual
within 14 days prior to the study visit were excluded from
the study.
The VL + UVA1 phototesting was performed utilizing the protocol published previously [6, 10, 19]. Briefly,
a single VL + UVA1 dose of 380 J/cm2 was administered
with a modified solar simulator: Solar Light LS1000 (Solar
Light Company Inc, Glenside, PA), with xenon arc lamp
and customized filters. Filtered spectral output consisted
of 1.4% UVA1 (340–400 nm), 96.3% VL (400–700 nm) and
2.28% IR (700–1800 nm). Spectroradiometric assessment
of the long UVA/Visible Light sources was performed
with a calibrated spectroradiometer OL-754 (Gooch and
Housego, Orlando, FL).
Sunscreen products used include SPF 50 chemical sunscreen without antioxidant blend (A); SPF 50 chemical
sunscreen with a three-ingredient AO blend (B); SPF 50
with five-ingredient AO blend (C); and an SPF 20 commercial tinted sunscreen (D). Untreated irradiated control
(U) did not have any sunscreen. Information regarding
products, including sunscreen active ingredients and AO
blends used in the study, are included in Table 1.
On visit 1 (Day 0), 24 h prior to VL + UVA1 exposure,
one hundred (100) microliters of products A, B and C
were applied on a standard 19 mm Hill Top Chamber
System® occlusive patch with a pad (Cliantha Research,
St. Petersburg, FL) and placed to the back of subjects on
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the marked individual sites for approximately 24 h. These
sites, corresponding to organic sunscreen with AO (and
without AO to serve as control for impact of occlusion),
were occluded to facilitate AO penetration by simulating
continuous product use. During visit 2 (Day 1 approximately 24 h after visit 1), the patches were removed and
products A, B and C were reapplied at the same occluded
sites at a concentration of 2 mg/cm2. One additional
site was treated with product D at 2 mg/cm2. The products were allowed to dry for 20 min following which all
treated sites A, B, C and D and an untreated site U were
irradiated with a VL + UVA1 dose of 380 J/cm2 at an irradiance of 95 mW/cm2 (~ 1 h and 6 min). Both sites U and
A served as positive controls: U because it was untreated
but irradiated, and site A because, although treated and
irradiated, there was no protection offered by this product against VL + UVA1. Additionally, product A followed
the same occlusion process as that for products B and C,
further serving as controls for any impact of occlusion.
Assessments of irradiated areas on the back were
done by digital cross-
polarized photography, investigators global assessment (IGA) score for pigmentation
(performed directly on the responses at the subject's
back), and diffuse reflectance spectroscopy (DRS). All
assessments were performed for all sites immediately
(visit 2, Day 1), 24 h (visit 3, Day 2) and 7 days (visit 4,
Day 8) after VL + UVA1 exposure. Table 2 includes the

ANTIOXIDANT SUNSCREENS FOR UVA1 AND VISIBLE LIGHT

pigmentation scale used in this study. For DRS, the
instrument consisted of a quartz halogen light source
(Ocean Optics, Boca Raton, FL), a bifurcated fibre
bundle (Multimode Fiber Optics, East Hanover, NJ), a
BWTEK Glacier spectrometer (B&W Tek, Plainsboro,
NJ), and a laptop. One leg of the fibre bundle was connected to the light source and the other to the spectrometer. Measurements were performed by placing
the common end of the fibre bundle gently against the
skin without perturbing blood flow. A reflectance spectrum was acquired in the range of 400–820 nm. Five (5)
measurements were collected from each site at all time
points after VL + UVA1 exposure. Measurements from
normal untreated and non-irradiated skin were also collected for normalization [6, 10, 19]. Apparent concentrations of haemoglobin and melanin, and area under
the curve from 400–700 nm (AUC, relative dyschromia)
were calculated from the DRS data as described elsewhere [20–22].
Primary data analysis was to compare the pigmentation scores as well as DRS results between control site
U (untreated but irradiated) and each of the 3 treated
sites B, C and D using paired t-tests with the Hochberg
multiple comparison methodology. For the 3 comparison results, the smallest p-value would be significant if
it was less than 0.017, the middle p-value if less than
0.033, and the largest p-value if less than 0.05. In case

Immediate

24 Hours

7 Days

F I G U R E 1 Representative cross-polarized photographs of sites U (untreated irradiated control); (A) (chemical sunscreen filters SPF
50 without antioxidant blend); (B) (chemical sunscreen filters SPF 50 with 3AO blend); (C) (chemical sunscreen filters SPF 50 with 5 AO
blend); and (D) (Commercial Tinted Sunscreen SPF 20) of a subject's back at various time points after irradiation (row 1: Immediately after,
row 2: 24 h and row 3: 7 days after VL + UVA1 irradiation)
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(a)

(b)

4

2

U

A

B

C

3

2

1

0

D

*

U

A

B

C

IGA Scores for Pigmentation

*

4

IGA Scores for Pigmentation

IGA Scores for Pigmentation

5

(c)

4

6

0

|
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1

0

D

*

2

U

24 Hours after Irradiation

Immediately after Irradiation

A

B

C

D

7 Days after Irradiation

F I G U R E 2 Average IGA scores for pigmentation for all sites immediately (a), 24 h (b) and 7 days after VL + UVA1 irradiation
(c). *represents statistically significant difference compared to site U. abbreviations: IGA, Investigator’s Global Assessment; UVA1,
ultraviolet A1; VL, visible light. U (untreated irradiated control); A (chemical sunscreen filters SPF 50 without antioxidant blend); B
(chemical sunscreen filters SPF 50 with 3AO blend); C (chemical sunscreen filters SPF 50 with 5 AO blend); and D (Commercial Tinted
Sunscreen SPF 20)
(a)

(b)

60

30

50

25

(c) 30

*

30

*

20

20
15
10

U

A

B

C

Immediately after Irradiation

D

0

20

15

10

5

5

10
0

Relative dyschromia

40

Relative dyschromia

Relative dyschromia

25

0
U

A

B

C

24 Hours after Irradiation

D

U

A

B

C

D

7 Days after Irradiation

F I G U R E 3 DRS measured relative dyschromia/AUC for all sites immediately (a), 24 h (b) and 7 days after VL + UVA1 irradiation
(c). * represents statistically significant difference compared to site U, † represents statistically significant difference compared to site A.
Abbreviations: DRS, diffuse reflectance spectroscopy; AUC, area under the curve; UVA1, ultraviolet A1; VL, visible light. U (untreated
irradiated control); A (chemical sunscreen filters SPF 50 without antioxidant blend); B (chemical sunscreen filters SPF 50 with 3AO blend);
C (chemical sunscreen filters SPF 50 with 5 AO blend); and D (Commercial Tinted Sunscreen SPF 20)

the t-test assumption of data distribution normality was
violated, the Wilcoxon signed rank test was performed
instead. As a secondary analysis, similar comparisons
were made between control site A (occluded with sunscreen without AO and irradiated) and each of the 3
treated sites B, C and D. Comparisons for pigmentation scores, DRS measured AUC and oxy-haemoglobin
were made for each time point, while those for melanin were performed for Day 7 only. All analyses were
done using OriginPro software (OriginLab Corporation,
Northampton, MA).

RES ULT S
Figure 1 consists of representative cross-polarized photographs of control and treated sites (U, A, B, C and D) of a

subject's back at various time points after irradiation (row
1: immediately after, row 2: 24 h and row 3: 7 days after
irradiation). Both IPD and erythema were observed immediately after irradiation with relatively less central and
surrounding clinical erythema observed for 5AO blend
sunscreen (sites C1) and tinted sunscreen (D1) (Figure 1
row 1). As represented in clinical photos obtained 7 days
after VL + UVA1 irradiation (Figure 1 row 3), both sites C3
and D3 had relatively less delayed tanning compared with
untreated site U3 and that treated with sunscreen without AO, site A3. The average IGA scores for pigmentation
as shown in Figure 2 a–c show that the site treated with
tinted sunscreen product (product D) was statistically significantly lighter than untreated irradiated control U at all
time points. Objective DRS measurements are represented
in Figures 3–5 showing changes in AUC/relative dyschromia, oxy-Hb and melanin content, respectively. Figure 3

ANTIOXIDANT SUNSCREENS FOR UVA1 AND VISIBLE LIGHT

  

(a)

(b)

0.5

(c)
0.20

0.12

P=0.07

0.4

0.15

0.3

Delta Oxy-Hb

Delta Oxy-Hb

0.08

0.2

P=0.02

0.04

Delta Oxy-Hb
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0.10

0.05

P=0.02 P=0.06

0.1
0.00

0.00
0.0

U

A

B

C

D

U

Immediately after Irradiation

U

A

B

C

D

A

B

C

D

7 days after Irradiation

24 Hours after Irradiation

F I G U R E 4 DRS measured change in oxy-Haemoglobin (delta oxy-Hb) for all sites immediately (a), 24 h (b) and 7 days (c) after
VL + UVA1 irradiation. Abbreviations: DRS, diffuse reflectance spectroscopy; Hb, haemoglobin; UVA1, ultraviolet A1; VL, visible light. U
(untreated irradiated control); A (chemical sunscreen filters SPF 50 without antioxidant blend); B (chemical sunscreen filters SPF 50 with
3AO blend); C (chemical sunscreen filters SPF 50 with 5 AO blend); and D (Commercial Tinted Sunscreen SPF 20)

melanin) were also performed. As shown with change in
oxy-Hb content in Figure 4a–c, there was less erythema at
sites C and D which was markedly below that of site U and
was approaching significance at 24 h and 7 days after irradiation time points. Figure 5 represents the same trend for
protection by showing change in melanin content 7 days
after VL + UVA1 irradiation with site C having statistically significantly lower melanin content compared to site
A. Figure 6 compares the absorption spectra of Products
C and D; the spectral output of the VL + UVA1 irradiation
source is also included demonstrating no impact of SPF on
VL + UVA1 protection offered.

0.40
0.35

Delta Melanin

0.30
0.25
0.20
0.15
0.10
0.05
0.00
U

A

B

C

D

7 days after Irradiation
F I G U R E 5 DRS measured change in melanin content
(delta melanin) for all sites 7 days after VL + UVA1 irradiation. †
represents statistically significant difference compared with site
A. Abbreviations: DRS, diffuse reflectance spectroscopy; UVA1,
ultraviolet A1; VL, visible light. U (untreated irradiated control); A
(chemical sunscreen filters SPF 50 without antioxidant blend); B
(chemical sunscreen filters SPF 50 with 3AO blend); C (chemical
sunscreen filters SPF 50 with 5 AO blend); and D (Commercial
Tinted Sunscreen SPF 20)

further supports the clinical findings and demonstrates
statistically significantly lower relative dyschromia for
both 5AO blend sunscreen (sites C) and tinted sunscreen
(D) compared with U and A at immediately after irradiation time point (Figure 3a), and for site C compared with
site A at 7 days after irradiation time point (Figure 3c).
Considering that relative dyschromia/AUC accounts for
overall lesion darkness resulting from combination of
pigmentation and erythema, separate comparisons for
erythema (delta oxy-Hb content) and pigmentation (delta

DISC USSION
VL + UVA1 irradiation has been linked to hyperpigmentation, an observation that is more common in individuals
with dark skin phenotypes [6]. Tinted products containing
pigmentary titanium dioxide and iron oxides have demonstrated reliable efficacy in decreasing this hyperpigmentation due to associated absorption spectra extending into
the VL waveband [23]. However, there are challenges
with wider acceptance of these tinted products due to issues with the product colour unfavourably altering skin
tone appearance and concerns for sunscreen noncompliance in many skin types [17]. This makes development
and efficacy evaluation of other means of photoprotection
against the VL waveband necessary.
This study demonstrated the photoprotective efficacy
of the 5AO blend sunscreen product against VL + UVA1
induced erythema and pigmentation. The results show
that based on clinical scoring, the site treated with tinted
sunscreen (Product D) had significantly lower pigmentation compared with untreated but irradiated skin at
all time points after irradiation (Figure 2). However,

RUVOLO et al.

  

(a)

|

7

(b)

2.5

SPF 50 5AO
SPF 20 Tinted

0.0005

Light Source

2.0

Absorbance

2

Irradiance (W/cm )

0.0004
1.5
0.0003
1.0

0.0002

0.5

0.0001

0.0

0.0000
300

320

340

360

380

400

420

440

wavelength (nm)

F I G U R E 6 Comparison of absorption spectra of products C and D and the spectral output of the VL + UVA1 irradiation source up to
450 nm (a) Complete spectral output of VL + UVA1 irradiation source along with data presented in 6a (b)

objective DRS analysis of relative dyschromia (Figure 3)
demonstrated that the 5AO blend sunscreen (Product C)
performed comparably (Figures 3 and 4), and at times
superior (Figure 5), to the tinted sunscreen (Product D)
against VL + UVA1 induced effects. The differences, in
clinical and instrumental findings, can be explained by
the inherent nature of the assessment techniques with
clinical scoring being subjective and discrete and DRS
being objective and continuous. The continuous nature
makes DRS relatively more sensitive in detecting changes
in skin colour and chromophore concentrations. As such,
the findings indicate that the 5AO blend sunscreen offered
photoprotection against VL + UVA1 induced effects without the tint which may lead to wider acceptability among
consumers.
The 3AO blend sunscreen (Product B) also demonstrated some photoprotective efficacy (Figures 3–5) against
VL + UVA1; however, unlike the 5AO blend sunscreen
(Product C), did not reach significance. The enhanced efficacy of the 5AO sunscreen could be associated with the
properties of the AOs that were not included as ingredients
in the 3AO blend, primarily licochalcone A, glycyrrhetinic
acid and vitamin C. Licochalcone A, derived from the roots
of Glycyrrhiza inflata, has been reported to have antioxidant properties through the inhibition of ROS production
in human fibroblasts irradiated by VL in both in vivo and
in vitro studies [7, 24]. Glycyrrhetinic acid is a licorice-
based compound known to have anti-inflammatory effects
against photoaging induced by UV irradiation, contain
antioxidant properties, and improve repair of UV-induced
pyrimidine dimers [25–27]. The lower concentration of
glycyrrhetinic acid and licochalcone A in the 5AO blend
sunscreen, 0.01% and 0.025%, respectively, and combined
effect with other ingredients may have resulted in the

decrease in hyperpigmentation effect observed in our study.
Topical solutions of vitamin C, or L-ascorbic acid, have
demonstrated antioxidant activity in skin and photoprotective action against UV radiation [28, 29]. Vitamin C's efficacy in reducing UV-induced pigmentation in Fitzpatrick
type III skin has been reported [30]. The results indicate
that the combination of these 3 AOs with Diethylhexyl
Syringylidene Malonate and Vitamin E provided a strong
AO defence in mitigating VL + UVA1 induced pigmentation. Nonetheless, the exact mechanism and associated histologic changes still need to be elucidated.
In conclusion, this study demonstrates photoprotective efficacy of an antioxidant-enriched organic sunscreen
against VL + UVA1 effects which was comparable to that
offered by a tinted mineral sunscreen. The combination
of efficacy and the cosmetic appearance of this product
may provide wider acceptability which is crucial considering the limited available means of protection against this
waveband. The study limitations include small number of
participants, limited skin phototype included, the use of a
non-validated IGA scale, unavailability of histologic data,
lack of colorimetric assessment performed on subjects
and the use of SPF 20 for tinted sunscreen product versus
the SPF 50 chemical sunscreen. Since SPF pertains to UVB
protection, it is not anticipated to have caused variation
in the protection offered against VL + UVA1. However,
this can be further evaluated in future studies. Future
studies may also consider consecutive pre-treatment of
AO-enriched sunscreens to ensure proper penetrance and
mimic how this product may be used by the typical consumer. Additionally, studies investigating the histologic
changes and associated mechanism for 5AO sunscreen
formulation in dark skinned individuals and efficacy in
light-skinned individuals are also warranted.
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